Squarepoint’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-868,200
| Closed | -$62.6M | – | 4855 |
|
|
2025
Q4 | $62.6M | Buy |
+868,200
| New | +$56.1M | 0.07% | 327 |
|
|
2025
Q1 | – | Sell |
-172,875
| Closed | -$5.03M | – | 5275 |
|
|
2024
Q4 | $5.03M | Buy |
172,875
+11,006
| +7% | +$460K | 0.01% | 1628 |
|
|
2024
Q3 | $7.43M | Buy |
161,869
+46,361
| +40% | +$2.01M | 0.01% | 1145 |
|
|
2024
Q2 | $4.72M | Buy |
115,508
+51,743
| +81% | +$1.48M | 0.01% | 1421 |
|
|
2024
Q1 | $1.63M | Buy |
63,765
+736
| +1% | +$11.5K | ﹤0.01% | 2232 |
|
|
2023
Q4 | $570K | Sell |
63,029
-95,562
| -60% | -$639K | ﹤0.01% | 2905 |
|
|
2023
Q3 | $1.01M | Buy |
158,591
+110,206
| +228% | +$949K | ﹤0.01% | 2314 |
|
|
2023
Q2 | $537K | Buy |
48,385
+9,441
| +24% | +$118K | ﹤0.01% | 2579 |
|
|
2023
Q1 | $598K | Buy |
38,944
+6,860
| +21% | +$151K | ﹤0.01% | 2200 |
|
|
2022
Q4 | $712K | Buy |
+32,084
| New | +$478K | ﹤0.01% | 2063 |
|
|
2022
Q1 | – | Sell |
-11,273
| Closed | -$268K | – | 3411 |
|
|
2021
Q4 | $268K | Buy |
+11,273
| New | +$269K | ﹤0.01% | 2514 |
|
|
2021
Q3 | – | Sell |
-23,491
| Closed | -$580K | – | 3353 |
|
|
2021
Q2 | $580K | Buy |
23,491
+10,875
| +86% | +$253K | ﹤0.01% | 2020 |
|
|
2021
Q1 | $275K | Buy |
12,616
+2,843
| +29% | +$69.6K | ﹤0.01% | 2470 |
|
|
2020
Q4 | $249K | Buy |
+9,773
| New | +$285K | ﹤0.01% | 2361 |
|
Other funds holding RNAM
Squarepoint's RNAM Position: Q1 2026 in Review
Squarepoint sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 868,200 shares — an estimated $62.6M sold.
Squarepoint first reported a position in RNAM in Q4 2020 and held it in 14 quarters. The position peaked at $62.6M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Squarepoint reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 868,200 Avidity Biosciences shares in Q1 2026, an estimated $62.6M.
- Squarepoint first reported a position in Avidity Biosciences in Q4 2020 and held it in 14 quarters.
- Squarepoint's Avidity Biosciences position peaked at $62.6M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.